| abstract |
A lyophilized formulation comprising an anti-epidermal growth factor (EGFR) drug and antibody (ADC) conjugate, a sugar, histidine and a surfactant, wherein said anti-EGFR ADC comprises an anti-EGFR antibody conjugated to a auristatin, wherein the anti-EGFR antibody comprises a heavy chain variable region comprising complementarity domain regions (CDR) that comprise the amino acid sequences set forth in SEQ ID NOS: 15, 16 and 17, and comprises a variable region light chain comprising CDRs comprising the amino acid sequences set forth in SEQ ID NOS: 20, 21 and 22. |